The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.
David Reim
Advertisement
Senior Director, Product & Strategy, IQVIA Digital
Articles by David Reim
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
ACS Calls Obesity a Condition That Must Be Treated with Medication and Surgery
5
